1300P - High expression of BAP1 is biomarker of better prognostic in advanced non-small cell lung cancer patients

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Yang-song Zuo
Authors Y. Zuo1, Z. Shen2
  • 1Department Of Respiration Medicine, Lianshui People's Hospital, 223400 - Lianshui, Jiangsu/CN
  • 2Sixth People's Hospital Shanghai Jiaotong University, 200233 - Shanghai/CN

Abstract

Background

Non small cell lung cancer (NSCLC) is the leading worldwide source of cancer-related deaths. Although some drugs targeting EGFR mutations were developed, most of advanced NSCLC is still incurable. New targets for anticancer drugs are demanded. BRCA1-associated protein-1 (BAP1) is a component of the ubiquitin proteasome system (UPS). The UPS has emerged as a potential target for anticancer drugs. The expression of BAP1 protein in patients with NSCLC has not been reported to date.

Methods

Here, we assessed BAP1 expression by Western blot in 103 cases patients with advanced NSCLC to investigate the impact of BAP1 on survival.

Results

Our data revealed 49 (47.5%) patients were classified as high expression of BAP1. Squamous cell carcinomas were more likely to be BAP1 high expressers compared to adenocarcinomas (55.8% vs. 32.3%, p= 0.001). High BAP1 expression was associated with lymph node metastasis (p= 0.008) as well as remote metastasis (p= 0.012) and was not associated with other clinical or pathological characteristics. In Kaplan-Meier survival analysis showed that patients with high BAP1 expression had a longer median survival compared to low expressers (23.2 vs. 14.7 months, p= 0.021) especially in the subset of squamous tumors (27.3 vs. 13.1 months, p= 0.013). Multivariate analysisrevealed that high BAP1expression was an independent lower risk for all 103 patients (HR = 0.61, 95% CI 0.32-0.71, p = 0.003).

Conclusions

BAP1 may be a useful prognostic factor of NSCLC patients and potential target for anticancer drugs.

Disclosure

All authors have declared no conflicts of interest.